---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-026965"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-06-03T11:00:17+00:00"
generated_at: "2026-06-03T11:05:43.135403+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin

## Summary
- James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
- Sam Lee becomes President and Chief Scientific Officer; Jim Martin remains CFO.
- Sapirstein has led 23 product launches and served as CEO of Contravir and Tobira Therapeutics.
- Company plans to appoint Sapirstein to the Board of Directors.

## SEC filing metadata
- accession: 0001493152-26-026965
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-06-03T11:00:17+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/0001493152-26-026965-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226026965/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-026965
- JSON: https://secwatch.observer/filing/0001493152-26-026965.json
- Plain text: https://secwatch.observer/filing/0001493152-26-026965.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.